Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Gómez-Cebrián N, Rojas-Benedicto A, Albors-Vaquer A, López-Guerrero JA, Pineda-Lucena A, Puchades-Carrasco L.

Metabolites. 2019 Mar 8;9(3). pii: E48. doi: 10.3390/metabo9030048. Review.

2.

Development of inhibitors of receptor protein tyrosine phosphatase β/ζ (PTPRZ1) as candidates for CNS disorders.

Pastor M, Fernández-Calle R, Di Geronimo B, Vicente-Rodríguez M, Zapico JM, Gramage E, Coderch C, Pérez-García C, Lasek AW, Puchades-Carrasco L, Pineda-Lucena A, de Pascual-Teresa B, Herradón G, Ramos A.

Eur J Med Chem. 2018 Jan 20;144:318-329. doi: 10.1016/j.ejmech.2017.11.080. Epub 2017 Nov 28.

3.

Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.

Pérez-Rambla C, Puchades-Carrasco L, García-Flores M, Rubio-Briones J, López-Guerrero JA, Pineda-Lucena A.

Metabolomics. 2017;13(5):52. doi: 10.1007/s11306-017-1194-y. Epub 2017 Mar 9.

4.

Metabolomics Applications in Precision Medicine: An Oncological Perspective.

Puchades-Carrasco L, Pineda-Lucena A.

Curr Top Med Chem. 2017;17(24):2740-2751. doi: 10.2174/1568026617666170707120034. Review.

5.

Pathophysiologic processes have an impact on the plasma metabolomic signature of endometriosis patients.

Vicente-Muñoz S, Morcillo I, Puchades-Carrasco L, Payá V, Pellicer A, Pineda-Lucena A.

Fertil Steril. 2016 Dec;106(7):1733-1741.e1. doi: 10.1016/j.fertnstert.2016.09.014. Epub 2016 Oct 25.

PMID:
27793377
6.

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.

Puchades-Carrasco L, Jantus-Lewintre E, Pérez-Rambla C, García-García F, Lucas R, Calabuig S, Blasco A, Dopazo J, Camps C, Pineda-Lucena A.

Oncotarget. 2016 Mar 15;7(11):12904-16. doi: 10.18632/oncotarget.7354.

7.

Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers.

Puchades-Carrasco L, Palomino-Schätzlein M, Pérez-Rambla C, Pineda-Lucena A.

Brief Bioinform. 2016 May;17(3):541-52. doi: 10.1093/bib/bbv077. Epub 2015 Sep 4. Review.

PMID:
26342127
8.

Nuclear magnetic resonance metabolomic profiling of urine provides a noninvasive alternative to the identification of biomarkers associated with endometriosis.

Vicente-Muñoz S, Morcillo I, Puchades-Carrasco L, Payá V, Pellicer A, Pineda-Lucena A.

Fertil Steril. 2015 Nov;104(5):1202-9. doi: 10.1016/j.fertnstert.2015.07.1149. Epub 2015 Aug 18.

PMID:
26297644
9.

Metabolomics in pharmaceutical research and development.

Puchades-Carrasco L, Pineda-Lucena A.

Curr Opin Biotechnol. 2015 Dec;35:73-7. doi: 10.1016/j.copbio.2015.04.004. Epub 2015 Apr 17. Review.

PMID:
25900094
10.

Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission.

Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F, San-Miguel JF, Pineda-Lucena A.

Clin Cancer Res. 2013 Sep 1;19(17):4770-9. doi: 10.1158/1078-0432.CCR-12-2917. Epub 2013 Jul 19.

11.

Differential metabolic profiling of non-pure trisomy 21 human preimplantation embryos.

Sánchez-Ribas I, Riqueros M, Vime P, Puchades-Carrasco L, Jönsson T, Pineda-Lucena A, Ballesteros A, Domínguez F, Simón C.

Fertil Steril. 2012 Nov;98(5):1157-64.e1-2. doi: 10.1016/j.fertnstert.2012.07.1145. Epub 2012 Sep 6.

PMID:
22959456

Supplemental Content

Loading ...
Support Center